 |
 |
|
Birmingham, Sandwell, Solihull and environs APC Formulary
Maintained by Midlands and Lancashire Commissioning Support Unit |
| Formulary Chapter 8: Malignant disease and immunosuppression - Full Section
|
Notes:
For the most up to date list of agents funded by the Cancer Drugs Fund, please see Cancer Drug Fund list |
| Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
|
08.01 |
Cytotoxic drugs
(0,1)
|
|
|
Side-effects of cytotoxic drugs
(0,1)
|
|
|
Drugs for cytotoxic-induced side-effects
(3,4)
|
|
08.01.01 |
Alkylating drugs
(9,0)
|
|
08.01.02 |
Anthracyclines and other cytotoxic antibiotics
(2,0)
|
|
08.01.03 |
Antimetabolites
(11,0)
|
|
08.01.04 |
Vinca alkaloids and etoposide
(1,2)
|
|
08.01.05 |
Other antineoplastic drugs
(36,1)
|
|
|
Amsacrine
(0,1)
|
|
|
Arsenic trioxide
(1,0)
|
|
|
Bevacizumab
(1,0)
|
|
|
Bexarotene
(1,0)
|
|
|
Bortezomib
(1,0)
|
|
|
Brentuximab vedotin
(1,0)
|
|
|
Cetuximab
(1,0)
|
|
|
Crisantaspase
(1,0)
|
|
|
Dacarbazine and Temozolomide
(2,0)
|
|
|
Erlotinib
(1,0)
|
|
|
Hydroxycarbamide
(1,0)
|
|
|
Ipilimumab
(1,0)
|
|
|
Mitotane
(1,0)
|
|
|
Panitumumab
(1,0)
|
|
|
Pentostatin
(0,1)
|
|
|
Platinum compounds
(1,2)
|
|
|
Porfimer sodium and temoporfin
(0,2)
|
|
|
Procarbazine
(1,0)
|
|
|
Protein kinase inhibitors
(22,1)
|
|
|
Taxanes
(4,0)
|
|
|
Topoisomerase I inhibitors
(1,1)
|
|
|
Trabectedin
(0,1)
|
|
|
Trastuzumab
(3,0)
|
|
|
Tretinoin
(0,1)
|
|
|
Vismodegib
(0,1)
|
|
08.02 |
Drugs affecting the immune response
(0,2)
|
|
|
Immunosuppressant therapy (0,0)
|
|
08.02.01 |
Antiproliferative immunosuppressants
(3,0)
|
|
08.02.02 |
Corticosteroids and other immunosuppressants
(5,2)
|
|
08.02.03 |
Anti-lymphocyte monoclonal antibodies
(12,0)
|
|
08.02.04 |
Other immunomodulating drugs
(4,3)
|
|
|
Interferon Alfa
(2,0)
|
|
|
Interferon beta
(6,0)
|
|
|
Interferon gamma (0,0)
|
|
|
Aldesleukin
(0,1)
|
|
|
BCG bladder instillation (0,0)
|
|
|
Canakinumab (0,0)
|
|
|
Dimethyl fumarate
(1,0)
|
|
|
Fingolimod
(1,0)
|
|
|
Glatiramer acetate
(1,0)
|
|
|
Histamine (0,0)
|
|
|
Lenalidomide, pomalidomide, and thalidomide
(2,0)
|
|
|
Mifamurtide
(1,0)
|
|
|
Natalizumab
(1,0)
|
|
|
Teriflunomide
(1,0)
|
|
08.03 |
Sex hormones and hormone antagonists in malignant disease (0,0)
|
|
08.03.01 |
Oestrogens
(1,1)
|
|
08.03.02 |
Progestogens
(3,0)
|
|
08.03.03 |
Androgens (0,0)
|
|
08.03.04 |
Hormone antagonists (0,0)
|
|
08.03.04.01 |
Breast cancer
(5,1)
|
|
08.03.04.02 |
Prostate cancer and gonadorelin analogues (0,0)
|
|
|
Gonadorelin analogues
(1,1)
|
|
|
Anti-androgens
(11,1)
|
|
|
Gonadotrophin-releasing hormone antagonists (0,0)
|
|
08.03.04.03 |
Somatostatin analogues
(5,0)
|
|
|
|
